{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:04:25Z","timestamp":1791572665680,"version":"4.3.4"},"reference-count":59,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamainternmed.2019.0086","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T11:36:06Z","timestamp":1553513766000},"page":"695","source":"Crossref","is-referenced-by-count":220,"title":["A Clinical Overview of Off-label Use of Gabapentinoid Drugs"],"prefix":"10.1001","volume":"179","author":[{"given":"Christopher W.","family":"Goodman","sequence":"first","affiliation":[{"name":"Department of Medicine, University of South Carolina School of Medicine, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan S.","family":"Brett","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of South Carolina School of Medicine, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"isc190001r2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015.","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"5","key":"isc190001r3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain: is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"isc190001r4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1056\/NEJMp0808659","article-title":"The Neurontin legacy: marketing through misinformation and manipulation.","volume":"360","author":"Landefeld","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"isc190001r5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","article-title":"Narrative review: the promotion of gabapentin: an analysis of internal industry documents.","volume":"145","author":"Steinman","year":"2006","journal-title":"Ann Intern Med"},{"issue":"20","key":"isc190001r6","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use.","volume":"361","author":"Vedula","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"isc190001r10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/papr.2013.13.issue-6","article-title":"A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy.","volume":"13","author":"Rauck","year":"2013","journal-title":"Pain Pract"},{"issue":"3","key":"isc190001r11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.diabres.2012.03.010","article-title":"A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial.","volume":"97","author":"Sandercock","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"issue":"21","key":"isc190001r12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"issue":"2","key":"isc190001r13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/jnnp.66.2.251","article-title":"Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial.","volume":"66","author":"Gorson","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"isc190001r14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00131402-200112000-00002","article-title":"Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy.","volume":"3","author":"Simpson","year":"2001","journal-title":"J Clin Neuromuscul Dis"},{"issue":"7","key":"isc190001r15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/j.pain.0000000000000554","article-title":"A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component.","volume":"157","author":"Atkinson","year":"2016","journal-title":"Pain"},{"issue":"2","key":"isc190001r16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1163\/156856901753420945","article-title":"Does gabapentin have an analgesic effect on background, movement and referred pain? a randomised, double-blind, placebo controlled study.","volume":"13","author":"McCleane","year":"2001","journal-title":"Pain Clin"},{"issue":"2","key":"isc190001r17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1163\/156856900750229825","article-title":"Gabapentin reduces chronic benign nociceptive pain: a double-blind, placebo-controlled cross-over study.","volume":"12","author":"McCleane","year":"2000","journal-title":"Pain Clin"},{"issue":"3","key":"isc190001r18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1163\/156856903767650718","article-title":"The effectiveness of gabapentin in patients with chronic radiculopathy.","volume":"15","author":"Yildirim","year":"2003","journal-title":"Pain Clin"},{"issue":"3","key":"isc190001r19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0304-3959(02)00255-5","article-title":"Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial.","volume":"99","author":"Serpell","year":"2002","journal-title":"Pain"},{"issue":"7","key":"isc190001r20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/01.BRS.0000112068.16108.3A","article-title":"Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury.","volume":"29","author":"Levendoglu","year":"2004","journal-title":"Spine (Phila Pa 1976)"},{"issue":"2","key":"isc190001r21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/10790268.2002.11753609","article-title":"Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial.","volume":"25","author":"Tai","year":"2002","journal-title":"J Spinal Cord Med"},{"issue":"4","key":"isc190001r22","doi-asserted-by":"publisher","first-page":"e0153037","DOI":"10.1371\/journal.pone.0153037","article-title":"Gabapentin for the management of chronic pelvic pain in women (GaPP1): a pilot randomised controlled trial.","volume":"11","author":"Lewis","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"isc190001r23","first-page":"481","article-title":"Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study.","volume":"27","author":"Bone","year":"2002","journal-title":"Reg Anesth Pain Med"},{"issue":"5","key":"isc190001r24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1682\/JRRD.2005.05.0082","article-title":"Efficacy of gabapentin in treating chronic phantom limb and residual limb pain.","volume":"42","author":"Smith","year":"2005","journal-title":"J Rehabil Res Dev"},{"issue":"5","key":"isc190001r25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/ene.2011.18.issue-5","article-title":"Gabapentin for the treatment of carpal tunnel syndrome: a randomized controlled trial.","volume":"18","author":"Hui","year":"2011","journal-title":"Eur J Neurol"},{"key":"isc190001r26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2377-4-13","article-title":"Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].","volume":"4","author":"van de Vusse","year":"2004","journal-title":"BMC Neurol"},{"issue":"4","key":"isc190001r27","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.","volume":"56","author":"Arnold","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"isc190001r28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s00415-004-0529-6","article-title":"A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.","volume":"251","author":"Hahn","year":"2004","journal-title":"J Neurol"},{"issue":"1-2","key":"isc190001r29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pain.2006.08.028","article-title":"Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.","volume":"127","author":"Kimos","year":"2007","journal-title":"Pain"},{"issue":"2","key":"isc190001r30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pain.2007.12.011","article-title":"Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study.","volume":"138","author":"Gordh","year":"2008","journal-title":"Pain"},{"issue":"3","key":"isc190001r31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.pain.2008.12.022","article-title":"A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.","volume":"142","author":"Dworkin","year":"2009","journal-title":"Pain"},{"issue":"5","key":"isc190001r32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.pain.2010.12.023","article-title":"Safety and efficacy of pregabalin in patients with central post-stroke pain.","volume":"152","author":"Kim","year":"2011","journal-title":"Pain"},{"issue":"1-2","key":"isc190001r33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pain.2007.06.033","article-title":"Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen.","volume":"136","author":"Vranken","year":"2008","journal-title":"Pain"},{"issue":"5","key":"isc190001r34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1212\/WNL.0b013e3181ccc6ef","article-title":"Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.","volume":"74","author":"Simpson","year":"2010","journal-title":"Neurology"},{"issue":"10","key":"isc190001r35","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.pain.2014.05.027","article-title":"A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy.","volume":"155","author":"Simpson","year":"2014","journal-title":"Pain"},{"issue":"12","key":"isc190001r36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1614292","article-title":"Trial of pregabalin for acute and chronic sciatica.","volume":"376","author":"Mathieson","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"isc190001r37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/j.pain.0000000000000143","article-title":"Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial.","volume":"156","author":"Holbech","year":"2015","journal-title":"Pain"},{"key":"isc190001r38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00508-010-1345-x","article-title":"Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence.","volume":"122","author":"Krcevski Skvarc","year":"2010","journal-title":"Wien Klin Wochenschr"},{"issue":"17","key":"isc190001r39","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/archinternmed.2010.319","article-title":"Pregabalin for the treatment of men with chronic prostatitis\/chronic pelvic pain syndrome: a randomized controlled trial.","volume":"170","author":"Pontari","year":"2010","journal-title":"Arch Intern Med"},{"issue":"8","key":"isc190001r40","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1468-1331.2010.02979.x","article-title":"Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial.","volume":"17","author":"van Seventer","year":"2010","journal-title":"Eur J Neurol"},{"issue":"2","key":"isc190001r41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1053\/j.gastro.2011.04.003","article-title":"Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial.","volume":"141","author":"Olesen","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"isc190001r42","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.pain.2011.01.055","article-title":"Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial.","volume":"152","author":"Gray","year":"2011","journal-title":"Pain"},{"issue":"6","key":"isc190001r43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.pmn.2017.07.003","article-title":"Management of sickle cell pain using pregabalin: a pilot study.","volume":"18","author":"Schlaeger","year":"2017","journal-title":"Pain Manag Nurs"},{"key":"isc190001r44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jclinepi.2018.05.007","article-title":"Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies.","volume":"101","author":"Olsen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"isc190001r45","first-page":"CD007938","article-title":"Gabapentin for chronic neuropathic pain in adults.","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"isc190001r46","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"issue":"8","key":"isc190001r48","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1001\/jama.2017.21547","article-title":"Gabapentin for chronic neuropathic pain.","volume":"319","author":"Moore","year":"2018","journal-title":"JAMA"},{"issue":"15","key":"isc190001r49","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain: United States, 2016.","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"20","key":"isc190001r51","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction appears in Neurology. 2011;77(6):603].","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"key":"isc190001r52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12871-015-0150-5","article-title":"Clinical practice guidelines for the management of neuropathic pain: a systematic review.","volume":"16","author":"Deng","year":"2016","journal-title":"BMC Anesthesiol"},{"issue":"10","key":"isc190001r53","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"isc190001r54","first-page":"CD007076","article-title":"Pregabalin for acute and chronic pain in adults.","author":"Moore","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"isc190001r55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/11585030-000000000-00000","article-title":"Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information.","volume":"34","author":"H\u00e4rmark","year":"2011","journal-title":"Drug Saf"},{"issue":"4","key":"isc190001r56","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin.","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"issue":"10","key":"isc190001r57","doi-asserted-by":"publisher","first-page":"e1002396","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study.","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"isc190001r58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/RMHP","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance.","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Healthc Policy"},{"issue":"3","key":"isc190001r59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMp1806486","article-title":"The FDA and the next wave of drug abuse: proactive pharmacovigilance.","volume":"379","author":"Throckmorton","year":"2018","journal-title":"N Engl J Med"},{"key":"isc190001r1","unstructured":"National Conference of State Legislatures. Prescribing policies: states confront opioid overdose epidemic. http:\/\/www.ncsl.org\/research\/health\/prescribing-policies-states-confront-opioid-overdose-epidemic.aspx. Published October 31, 2018. Accessed December 23, 2018."},{"key":"isc190001r7","unstructured":"United States Department of Justice. Justice Department announces largest health care fraud settlement in its history: Pfizer to pay $2.3 billion for fraudulent marketing. https:\/\/www.justice.gov\/opa\/pr\/justice-department-announces-largest-health-care-fraud-settlement-its-history. Published September 2, 2009. Accessed December 23, 2018."},{"key":"isc190001r8","unstructured":"Consumer Reports. Pfizer hit with $43 million settlement for misleading marketing of drugs. https:\/\/consumerist.com\/2012\/12\/12\/pfizer-hit-with-43-million-settlement-for-misleading-marketing-of-drugs. Published September 12, 2012. Accessed December 23, 2018."},{"key":"isc190001r9","unstructured":"IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.: a review of 2017 and outlook to 2022. https:\/\/www.iqvia.com\/institute\/reports\/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022. Published April 19, 2018. Accessed February 11, 2019."},{"key":"isc190001r47","unstructured":"International Association for the Study of Pain. IASP terminology. https:\/\/www.iasp-pain.org\/terminology?navItemNumber=576. Published December 14, 2017. Accessed December 23, 2018."},{"key":"isc190001r50","unstructured":"RosenquistEWK. Overview of the treatment of chronic non-cancer pain. https:\/\/www.uptodate.com\/contents\/overview-of-the-treatment-of-chronic-non-cancer-pain. Last updated February 5, 2019. Accessed February 11, 2019."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamainternalmedicine\/article-pdf\/179\/5\/695\/17551289\/jamainternal_goodman_2019_sc_190001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T12:25:18Z","timestamp":1557231918000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2019.0086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2019.0086","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735389876.793566289","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.735389876.793559305","asserted-by":"object"}]},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}